Starting in June, Cigna members will have access to a Humira biosimilar used to treat a range of inflammatory conditions for $0 out of pocket. The biosimilar costs nearly 85% less than Humira and will lower patient costs by approximately $3,500 annually.
Biosimilars are nearly identical versions of biologics previously approved by the Food and Drug Administration. The newly accessible drug is available through Accredo, Cigna’s specialty pharmacy.
Plan sponsors are advised to share news of this this cost-saving alternative with members.
For additional information, contact your Bukaty benefits consultant at 913.345.0440.
